This article is more than 5 years old. Information may no longer be current.
Ophthotech announces leadership changes
Click Here to Manage Email Alerts
Ophthotech is making several changes in senior leadership, the company announced in a press release.
Effective July 1, David R. Guyer, MD, cofounder, CEO and chairman of the board, will transition to executive chairman, and Glenn P. Sblendorio, president and chief financial officer, will become CEO. He will also retain his role as president.
Effective immediately, David F. Carroll, previously senior vice president of finance, has been promoted to chief financial officer and treasurer.
“As the company continues to review strategic alternatives and actively explores potentially obtaining rights to additional products, product candidates and technologies to treat ophthalmic diseases, particularly those of the back of the eye, David Guyer’s extensive expertise and experience brings a wealth of ophthalmology knowledge that is critical as we execute a strategy to maximize shareholder value,” Sblendorio said in the release. “In this newly created role of executive chairman, I look forward to David’s continued guidance and contributions to Ophthotech. Additionally, I look forward to working closely with Dave Carroll in his new position as chief financial officer and to his continued contributions to the company.”